# Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

> **NCT00740129** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Paget's Disease of the Bone

## Interventions

- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT00740129
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-21
- **Primary completion:** 2011-03-14
- **Final completion:** 2011-03-14
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740129, "Re-treatment of Participants With Paget's Disease Using Zoledronic Acid". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00740129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*